3-methoxytyramine has been researched along with 4-butyrolactone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chrapusta, SJ; Egan, MF; Karoum, F; Wyatt, RJ | 2 |
| Brown, EE; Cumming, P; Damsma, G; Fibiger, HC | 1 |
| Salama, AI; Saller, CF | 1 |
| Spaan, SJ; Westerink, BH | 1 |
| Kehr, W | 1 |
| Bonnet, JJ; Costentin, J; Thibaut, F; Vaugeois, JM | 2 |
8 other study(ies) available for 3-methoxytyramine and 4-butyrolactone
| Article | Year |
|---|---|
gamma-Butyrolactone-sensitive and -insensitive dopamine release, and their relationship to dopamine metabolism in three rat brain regions.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Butyrolactone; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Frontal Lobe; Homovanillic Acid; In Vitro Techniques; Male; Nucleus Accumbens; Pargyline; Rats; Rats, Sprague-Dawley | 1992 |
Interstitial 3-methoxytyramine reflects striatal dopamine release: an in vivo microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Butyrolactone; Animals; Antidepressive Agents; Apomorphine; Bupropion; Corpus Striatum; Dialysis; Dopamine; Haloperidol; Homovanillic Acid; Kinetics; Male; Propiophenones; Rats; Rats, Inbred Strains; Tetrodotoxin | 1991 |
3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Buspirone; Carbazoles; Chlorpromazine; Clozapine; Corpus Striatum; Dopamine; Dopamine Antagonists; Fluphenazine; Haloperidol; Male; Molindone; Pargyline; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Regression Analysis | 1986 |
On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Butyrolactone; Animals; Apomorphine; Benztropine; Brain; Chlorpromazine; Dextroamphetamine; Dopamine; Female; Haloperidol; Homovanillic Acid; Kinetics; Morphine; Nomifensine; Oxotremorine; Rats; Rats, Inbred Strains; Reserpine | 1982 |
3-Methoxytyramine and normetanephrine as indicators of dopamine and noradrenaline release in mouse brain in vivo.
Topics: 4-Butyrolactone; Animals; Apomorphine; Brain; Bromocriptine; Dextroamphetamine; Dopamine; Kinetics; Lisuride; Male; Mice; Norepinephrine; Normetanephrine; Pargyline; Receptors, Dopamine | 1981 |
Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not gamma-butyrolactone-resistant dopamine release.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Butyrolactone; Animals; Brain Chemistry; Cerebral Cortex; Clozapine; Dopamine; Dopamine Antagonists; Haloperidol; Homovanillic Acid; Male; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Dopamine | 1993 |
In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmission.
Topics: 4-Butyrolactone; Animals; Benzazepines; Cerebellum; Corpus Striatum; Dextroamphetamine; Dopamine; Dopamine Agents; Levodopa; Male; Mice; Receptors, Dopamine D1 | 1996 |
Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice.
Topics: 4-Butyrolactone; Analysis of Variance; Animals; Cerebellum; Cocaine; Dextroamphetamine; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; GABA Modulators; Injections, Intravenous; Levodopa; Mazindol; Mice; Neostriatum; Protein Binding; Tritium | 1996 |